The move away from opioids in postsurgical pain management is reshaping clinical practice across the United States. | In an era of continued addiction risk, non-opioid pain therapies are gaining traction, but access barriers persist. Here’s what’s standing in the way.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
Of the 400 million patients worldwide diagnosed with rare diseases, about 250 million of them live in North and Southeast Asia1.…
LAS VEGAS — As drug costs and spending continue to rise, the demand for solutions opens the door to closer collaboration between…
Amid multiple efforts to rein in steep drug costs in the U.S., Colorado has received the all-clear to take matters into its own…
Early-onset cancers are rising among adults 18–49, reshaping how patients are diagnosed, supported, and engaged. This report…
Pharma companies need to strengthen and modernize patient support programs to reflect rising rates of cancer in adults aged 18 to…
